Peptidoglycan from immunobiotic lactobacillus rhamnosus improves resistance of infant Mice to respiratory syncytial viral infection and secondary pneumococcal pneumonia

51Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

Abstract

Several research works have demonstrated that beneficial microbes with the capacity to modulate the mucosal immune system (immunobiotics) are an interesting alternative to improve the outcome of bacterial and viral respiratory infections. Among the immunobiotic strains with the capacity to beneficially modulate respiratory immunity, Lactobacillus rhamnosus CRL1505 has outstanding properties. Although we have significantly advanced in demonstrating the capacity of L. rhamnosus CRL1505 to improve resistance against respiratory infections as well as in the cellular and molecular mechanisms involved in its beneficial activities, the potential protective ability of this strain or its immunomodulatory cellular fractions in the context of a secondary bacterial pneumonia has not been addressed before. In this work, we demonstrated that the nasal priming with non-viable L. rhamnosus CRL1505 or its purified peptidoglycan differentially modulated the respiratory innate antiviral immune response triggered by toll-like receptor 3 activation in infant mice, improving the resistance to primary respiratory syncytial virus (RSV) infection, and secondary pneumococcal pneumonia. In association with the protection against RSV-pneumococcal superinfection, we found that peptidoglycan from L. rhamnosus CRL1505 significantly improved lung CD3+ CD4+ IFN-γ+ , and CD3+ CD4+ IL-10+ T cells as well as CD11c+ SiglecF+ IFN-β+ alveolar macrophages with the consequent increases of IFN-γ, IL-10, and IFN-β in the respiratory tract. Our results also showed that the increase of these three cytokines is necessary to achieve protection against respiratory superinfection since each of them are involved in different aspect of the secondary pneumococcal pneumonia that have to be controlled in order to reduce the severity of the infectious disease: lung pneumococcal colonization, bacteremia, and inflammatory-mediated lung tissue injury.

References Powered by Scopus

Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000

3042Citations
N/AReaders
Get full text

Inhibition of pulmonary antibacterial defense by interferon-γ during recovery from influenza infection

500Citations
N/AReaders
Get full text

Viral and Bacterial Interactions in the Upper Respiratory Tract

488Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Postbiotics-parabiotics: The new horizons in microbial biotherapy and functional foods

394Citations
N/AReaders
Get full text

Probiotics-based foods and beverages as future foods and their overall safety and regulatory claims

112Citations
N/AReaders
Get full text

Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055

100Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Clua, P., Kanmani, P., Zelaya, H., Tada, A., Humayun Kober, A. K. M., Salva, S., … Villena, J. (2017). Peptidoglycan from immunobiotic lactobacillus rhamnosus improves resistance of infant Mice to respiratory syncytial viral infection and secondary pneumococcal pneumonia. Frontiers in Immunology, 8(AUG). https://doi.org/10.3389/fimmu.2017.00948

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 28

72%

Researcher 7

18%

Professor / Associate Prof. 3

8%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Immunology and Microbiology 10

29%

Agricultural and Biological Sciences 9

26%

Biochemistry, Genetics and Molecular Bi... 8

24%

Medicine and Dentistry 7

21%

Save time finding and organizing research with Mendeley

Sign up for free